Filing Details

Accession Number:
0001209191-21-002342
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-06 18:49:35
Reporting Period:
2021-01-04
Accepted Time:
2021-01-06 18:49:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI Biological Products, (No Disgnostic Substances) (2836) 463872213
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724310 J. Ryan Watts C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-01-04 1,300 $65.21 2,410,012 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 1,700 $66.63 2,408,312 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 1,224 $68.26 2,407,088 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 9,900 $70.02 2,397,188 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 11,896 $70.82 2,385,292 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 8,683 $71.77 2,376,609 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 9,443 $72.63 2,367,166 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 7,322 $73.78 2,359,844 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 1,100 $74.52 2,358,744 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 1,620 $76.07 2,357,124 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 1,740 $77.29 2,355,384 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 9,482 $78.41 2,345,902 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 4,208 $79.57 2,341,694 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 1,400 $80.25 2,340,294 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 7,539 $81.66 2,332,755 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 7,410 $82.44 2,325,345 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 1,225 $83.43 2,324,120 No 4 S Indirect See footnote
Common Stock Disposition 2021-01-04 1,142 $84.24 2,322,978 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2021-01-04 60,000 $0.00 60,000 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2021-01-04 180,000 $0.00 180,000 $70.86
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,000 No 4 A Direct
180,000 2031-01-03 No 4 A Direct
Footnotes
  1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.95 to $65.59 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
  4. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.32 to $67.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  5. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.80 to $68.65 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  6. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.29 to $70.28 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  7. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.29 to $71.28 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  8. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.30 to $72.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  9. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $72.30 to $73.27 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  10. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $73.30 to $74.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  11. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $74.36 to $75.34 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  12. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $75.56 to $76.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  13. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $76.93 to $77.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  14. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $77.94 to $78.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  15. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $78.94 to $79.91 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  16. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $79.99 to $80.60 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  17. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $81.03 to $82.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  18. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $82.03 to $83.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  19. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $83.07 to $84.01 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  20. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $84.16 to $84.25 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  21. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
  22. 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
  23. 25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.